Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n ¼ 30) had unfavorable first remission cytogenetics, progression from myelodysplasia or active disease due to induction failure or relapse. Conditioning was i.v. BU, targeted to a first-dose plasma area under the curve (AUC) of 700-900 lM min, VP-16 at 30 mg/kg of adjusted ideal body weight and fractionated TBI (FTBI) at 1200 cGy in 10 fractions. GVHD prophylaxis was CsA and mycophenolate mofetil. Regimen-related toxicities (Bearman) included grade II mucositis in 29 patients (97%) and grade III in one patient, grade II-III sinusoidal obstructive syndrome in 2 patients (7%), and grade 2-3 (CTC) skin toxicity in 8 patients (27%). The 30-and 100-day TRMs were 0 and 7% respectively. The median follow-up was 83.7 months (60.7-96.4) for surviving patients. The 5-year overall and disease-free survival was 40% for all patients. Cumulative 5-year relapse incidence (RI) was 23% and TRM was 37%. We have shown promising OS and RI in these poor-risk patients, who typically have few curative options.
Introduction
Relapse is the major cause of treatment failure in allogeneic hematopoietic cell transplant patients with poor-risk leukemia, especially those with active disease due to induction failure or relapse. Relapse rates ranging from 28 to 69% have been demonstrated depending on the particular study regimen and patient population. [1] [2] [3] [4] [5] A key element in obtaining stable remission in patients with active disease is the intensity of the preparative regimen. High-intensity regimens, while improving relapse rates, tend to offset this gain with an increased TRM due to regimen-related toxicity, tissue damage and increased incidence and/or severity of GVHD.
In an effort to improve relapse incidence (RI) while reducing TRM, we have developed a BU, fractionated TBI (FTBI), etoposide (VP-16) regimen, tailored to reduce extramedullary toxicity. The rationale for choosing this combination of agents was as follows: (1) the drugs do not exhibit cross-resistance, ( 2) all three demonstrate doseresponse curves, (3) VP16, a topoisomerase II inhibitor synergizes in vitro with an alkylating agent (like BU) to kill HL-60 promyelocytic leukemia cells 6 and (4) these three agents in various combination regimens (which may also include CY) show some clinical efficacy for allogeneic and autologous hematopoietic cell transplant in relapsed leukemia.
The BU/FTBI/VP-16 combination was first tested by our group in a phase-1/2 trial using oral BU before the availability of IV BU. 7 Escalating doses of oral BU were added to a preparative regimen of FTBI (12 Gy in 10 fractions) and VP-16 (60 mg). The maximum tolerated dose of BU was 12 mg/kg (oral) and the median plasma area under the curve (AUC) for the patients treated with 11 mg/kg (MTD-1) was 892 mM min (460-1627). BU doses 47 mg/kg were associated with improved disease-free survival.
In the current study, IV BU was used for its more consistent bioavailability and lower incidence of sinusoidal obstructive syndrome (SOS) 8 and was targeted to a firstdose plasma AUC of 700-900 mM min, based on data from the previous phase-2 trial of oral BU. The VP-16 dose was lowered to 30 mg/kg based on data from a trial by Kroger et al. showing significant decreases in hepatic toxicity, SOS and acute GVHD with increased OS for the 30 mg/kg VP-16 dose vs the 45 mg/kg dose in Bu/Cy/VP-16 regimens. 9 Based on the literature and our own preliminary data, we designed and performed this prospective phase-2 trial of IV BU, targeted to an AUC of 700-900 mM min, VP-16 and FTBI conditioning, before allogeneic transplant in poor-risk leukemia patients at City of Hope.
Patients and methods

Inclusion criteria
The Internal Review Board (IRB) at City of Hope approved this study and all patients were consented according to the Declaration of Helsinki. Study enrollment occurred between February 2000 and October 2004 at City of Hope, Duarte and also one patient at Good Samaritan, Phoenix. Enrollment for this protocol included patients of age X16 to p50, with advanced or poor-risk acute leukemia based on the following criteria: acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) after induction failure or in relapse, and AML in first remission (CR1) with unfavorable cytogenetics or evolved from myelodysplasia. Eligibility also required the availability of an HLA-identical sibling donor. Organ function requirements were as follows: cardiac ejection fraction X50%, serum creatinine p1.2 or creatinine clearance 480 mL/min, bilirubin pserum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) o5 times the upper limit of normal, FEV 1 and diffusion capacity 450% predicted normal value. Additional criteria were absence of active infection and time from last chemotherapy X28 days.
Patients
Patient characteristics and pre-transplant status are shown in Table 1 . Six patients in CR1 were placed on this protocol because of unfavorable cytogenetics, based on South west Oncology Group criteria, 10, 11 or progression from MDS. Three patients with AML in CR1 with unfavorable cytogenetics had t(9:22), 11q 23 abnormality and a complex karyotype. In all, 22 patients had active AML or ALL due to induction failure or relapse. Two patients had active, untreated MDS (refractory anemia with excess blasts (RAEB)-t), which would now be classified as AML based on the current WHO classification. 12 Of the 24 patients with induction failure or relapse, median WBC was 3.35 Â 10 9 /L (0.9-29.2), blasts in BM were 16.5% (0-95) and blasts in peripheral blood were 3.5% (0-92). Two patients with induction failures had fewer than 5% blasts in the marrow at the time of transplant; this reflects the fact that following pre-treatment before transplant conditioning, the ANC and plt counts had not recovered sufficiently to fulfill the definition of CR. Patient comorbidity at the time of transplant was calculated using the Pretransplant Assessment of Mortality 13 score calculator available on the internet at http://cdsweb.fhcrc. org/pam/. The median Pretransplant Assessment of Mortality score was 26 with a range of 22-34.
Treatment regimen
The treatment regimen is diagramed in Figure 1 . Before start of the preparative regimen, on day 17 (with day 0 ¼ transplant day), phenytoin was administered 300 mg orally three times for 1 day, then 300 mg/day orally or IV for 14 days to prevent seizures. On day 13, a test dose of BU was administered at 22 mg/m 2 body surface area. After measuring plasma concentrations at day 12, the subsequent doses were adjusted to target an AUC between 700 and 900 mM min, based on the patient body surface area. The maximum possible dose was set to 27.25 mg/m 2 . On day 11 calculated BU dose was administered and blood levels re-tested. Further dose adjustments were made for AUCs 41000 mM min. The calculated target dose was administered in 14 doses over 4 days. On days À6 through À3, a total of 1200 cGy FTBI was given in 10 fractions. On day 2, VP-16 was dosed at 30 mg/kg of adjusted ideal bodyweight. PBSCs were transfused on day 0. GVHD prophylaxis was CsA and mycophenolate mofetil, starting at day 1 for all patients. After patients were able to eat and drink, IV administration of GVHD prophylaxis was switched to the oral route. Mycophenolate mofetil taper was begun at day 100 and CSA taper began at 6 months if there was no evidence of GVHD.
BU AUC calculation
Serial heparinized blood samples (4 mL each) were collected around the BU test dose at the following times; predose, immediately before the end of the BU infusion, and then at 15, 30, 60, 180 and 240 min after the end of the infusion. The same sampling schedule was repeated around the second dose in most patients. BU concentrations in plasma were measured according to the previously published gas-liquid chromatographic method of Chen et al. 
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BU AUC was estimated using a one-compartment pharmacokinetic model with first-order elimination in ADAPT II software (USC Biomedical Simulations Resource, Los Angeles, CA, USA). The goodness-of-fit of the model-derived AUC was further confirmed by noncompartmental methods using the rule of linear trapezoids.
Statistics OS estimates were calculated based on the product-limit method, and 95% confidence intervals (CIs) were calculated using the logit transformation and the Greenwood variance estimate. 15 Cumulative RI was calculated controlling for non-relapse related death as a competing risk and conversely, TRM was calculated controlling for relapse as a competing risk. 16 Differences between survival curves were assessed by log-rank or Gray's test 17 as appropriate. The significance of demographic and treatment features collected from hematopoietic cell transplant recipients was assessed using Cox proportional-hazards regression analysis 18 and its competing-risks analog. 19 The following parameters were included in the analysis: patient age, sex, disease group (AML/CR1, AML/R1, AML/IF, ALL), second dose BU AUC (per unit increase and also per 100-unit increase), pre-conditioning BM blasts, pre-conditioning peripheral cell blasts, cytogenetics (intermediate vs unfavorable), WBC count at diagnosis (continuous), WBC count pre-conditioning (continuous). Statistical significance was defined at the P-value less than or equal to 0.05 level.
Results
Engraftment
Engraftment was defined as the first day of ANC 4500 per microliter of blood, when counts were maintained above 500 for 3 consecutive days. All patients engrafted successfully. The median time, post transplant, to reach an ANC of X500/mL was 11 days (range 8-23), and a plt count X20/mL was 18 days (range 14-65). BM at day 30 was negative for leukemia for all patients excepting one with persistent disease.
Regimen-related toxicity Regimen-related toxicity (RRT) was rated for severity according to the Bearman scoring system, except skin which used CTC v.3.0. 20 In all, 29/30 patients developed grade II mucositis, requiring opioid infusions and total parenteral nutrition, and one patient required intubation for airway protection. SOS of the liver grades II and III occurred in two patients (7%). Skin toxicity grades 2-3 (CTC) occurred in eight patients (27%) and manifested as an erythematous rash involving axilla and groin areas as previously described by Linker.
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Graft-versus-host disease The total incidence of acute GVHD, as defined by Glucksberg et al. 22 was 63% for grades II-IV and 23% for grades III-IV. Chronic GVHD, by the classical limited/ extensive classification, 23, 24 occurred at a rate of 82% overall, 5/28 patients (18%) having limited disease and 18/28 (64%) with extensive. Cumulative incidence of aGVHD calculated with death as a competing risk was 0.47 (95% CI: 0.30, 0.65) at 30 days and 0.63 (95% CI: 0.45, 0.79) at 100 days. Cumulative incidence of cGVHD with death as a competing risk was 0.40 (95% CI: 0.24, 0.59) at 1 year and 0.53 (95% CI: 0.35, 0.71) at 5 years. Two patients died before day 100, never entering the risk-set for chronic GVHD. The median time of follow-up was 83.7 months (60.7-96.4) for surviving patients. At analysis date, eight patients had completely discontinued immunosuppression, two used only local therapy, one used cyclosporin 50 mg twice daily on alternating days with 10 mg prednisone, and one took 10 mg prednisone daily. Figure 2 plots the first-and second-dose BU AUCs. BU test-dose AUCs are available for 30 patients and seconddose AUCs are available for 28 patients. Of the 30 patients with test-dose AUCs, 23 had AUCs below the target range, 5 were within the range and 2 were above the range. Of the 23 patients with a test dose below the range, for seconddose AUCs, the repeat dose came within the range for 8 patients, went above the range for 3 patients and remained below the range for 12 patients. Both patients whose test dose was above the target range had repeat-dose AUCs within the range after dose adjustments. The median first-dose AUC was 518 mM min, while the median second dose AUC was 684 mM min. No patient had a BU AUC 41000 mM min at second dose, so further adjustments were unnecessary.
BU dose adjustment
Outcomes
The median time of follow-up was 46.3 months for all patients (range 2.0-96.4), and 83.7 months (60.7-96.4) for surviving patients. In all, 18 of 30 patients (60%) had died Intensified allo regimen for poor-risk leukemia AS Stein et al as of the date of analysis, and the cause of death is reported in Table 2 . The 5-year OS rate was 40% for all patients, with a CI of 23-57%, with the survival curve shown in Figure 3a . Disease-free survival at 5 years was also 40%. Figure 3b depicts 5-year cumulative RI (23%; CI 11-42%) and TRM (37%; CI 21-55%) for the total study group, calculated as competing risks. The 30-day and 100-day TRMs were 0 and 7% respectively. Four distinct subgroups were compared for 5-year OS and RI, AML/CR1 (n ¼ 6), AML/R1 (n ¼ 6) AML/IF (n ¼ 10) and active ALL (n ¼ 6). 5-year OS for the groups was 67% (CI 20-90%, AML/CR1), 50% (CI 11-80%, AML/R1), 30% (7-38%, AML/IF) and 33% (CI 5-68%, ALL); no significant differences were seen between groups. The 5-year cumulative incidence of relapse controlling for TRM in the groups was 0% (AML/CR1), 0% (AML/R1), 30% (CI 9-65%, AML/IF) and 50% (CI 13-87%, ALL); no significant differences were seen between groups. A proportionalhazards model regression analysis was performed to look at second-dose BU AUC as a continuous-variable predictor of relapse with non-relapse death as a competing risk; AUC was borderline significant at P ¼ 0.06. The risk ratio was 1.00 with 95% CI (1.00, 1.01) per unit increase of AUC. When calculated per 100 unit increase of AUC, the risk ratio was 1.62 with 95% CI (0.98, 2.68). BU AUC as a continuous variable was also analyzed as a risk factor for TRM (with relapse death as a competing risk) and GVHD incidence. AUC was borderline significant as a risk factor for TRM (P ¼ 0.06), but showed no significant impact on either aGVHD or cGVHD. In all, 12 of 30 patients were living at the analysis date of this report. At last follow-up, surviving patients had the following Karnofsky performance status scores: eight were 90%, one was 80-90%, two at 80% and one at 70-80%.
Discussion
The goal of this study was to intensify the conditioning regimen for high-risk leukemia transplant patients to decrease the incidence of relapse while minimizing associated morbidity and mortality. This targeted BU/FTBI/ VP-16 pre-transplant conditioning regimen was very effective in achieving disease control in patients with high-risk myeloid malignancy, both those in remission and with active disease at the time of hematopoietic cell transplant. Among the patients in first remission (with unfavorable cytogenetics or evolved from MDS, n ¼ 6) and those with relapsed AML (n ¼ 6) there were no relapses post transplant. The 5-year OS and disease-free survival of 40% for the total population compare favorably with the literature wherein survival percentages for advanced patients are 17-36%. 1,2,4,5 Modulating the preparative regimen to decrease toxicity resulted in a very low 100-day TRM of 7%, with an overall 5-year TRM of 37% primarily due to complications of cGVHD. Based on our median Pretransplant Assessment of Mortality score 13 of 26 (range 22-34), the expected 2-year mortality is 56% (53-60), which corresponds to an OS at 2 years of 44%. Our 2-year OS (see Figure 3a) was 63% (95% confidence of 44-78%), so survival is at, or greater than, predicted outcomes based on the Pretransplant Assessment of Mortality score.
This IV BU protocol achieved the target AUC of 700-900 mM min in 54% of patients at second dose. The data presented in Figure 2 illustrates the difficulty of targeting BU exposures within a narrow therapeutic range. Even though IV BU levels are more stable than oral dosing Intensified allo regimen for poor-risk leukemia AS Stein et al levels, the use of PK measurements is valuable, as dose adjustment was required frequently. The chosen range of 700-900 mM min, with a true target of 800 mM min, in the setting of normal intrapatient pharmacokinetic variability, is probably impractical. The majority of the AUCs outside the range were below the lower limit of 700 mM min. In several cases, this was due to the self-imposed limitation on the maximum allowable dose increase (0.8 mg/ kg ¼ 27.25 mg/m 2 ). Interestingly, if we had chosen a true target of 800 mM min and increased the range to ± 25% (that is, 600-1000 mM min), 22 of the 28 patients with repeat AUCs would have been in the target range.
Despite the increased intensity of this regimen, mortality due to regimen-related toxicity (RRT) was improved compared with other high-intensity regimens in the literature and is reflected in the 7% 100-day TRM. [2] [3] [4] 9 The primary toxicity was mucositis, with 29/30 patients experiencing grade II and 1/30 experiencing grade III.
However, other complications, including SOS, were rare and there were no deaths attributable to RRT. Bu/Cy/TBI, Bu/Cy/VP-16 and Cy/TBI/VP16 high-intensity regimens have resulted in multiple lethal RRT events ranging from 5 to 16% of patients, typically lung toxicity and SOS. [2] [3] [4] 9 Regulation of the BU dose using AUC and lowering of the etoposide dose to 30 mg/kg, likely both contributed to prevention of lethality from RRT. 9, 25 In this study, the incidence of aGVHD II-IV was 63% and cGVHD was 82%. In comparison, the CSA/mycophenolate mofetil prophylactic regimen used by Dean et al., for myeloablative matched-sibling bone-marrow transplants shows rates of 58% acute and 42% chronic GVHD. 26 Cutler et al., for peripheral blood myeloablative transplants using sirolimus/tacrolimus prophylaxis, saw GVHD rates of 20.5% acute and 59.1% chronic GVHD. 27 The relatively high rates of GVHD in our study are possibly due to the use of PBSCs, the advanced disease stage of the patients and the significant mucosal injury related to this conditioning regimen. To address this issue, in our follow-up study, we have replaced the GVHD prophylaxis regimen with tacrolimus/sirolimus. Recent studies using tacrolimus/ sirolimus for GVHD prophylaxis at this institution show lower rates of GVHD than CSA/mycophenolate mofetil regimens following peripheral blood transplants. 28, 29 Despite the rate of GVHD, survival in such a poor-prognosis group of patients is relatively high and the 12 surviving patients are not severely disabled, as indicated by Karnofsky performance status scores (average 86%, median 90%). In all, 8 of these 12 patients had completely discontinued immunosuppressive therapy at analysis date, while the remaining 4 were on minimal immunosuppression.
Disease-free survival of 40% at 5-years and RI of 23% is particularly encouraging for patients with advanced leukemias (ALL and AML). The prognosis for AML patients in active relapse or induction failure is so poor that they are not considered eligible for transplant at many institutions. OS rates of 50% for AML patients in R1 and 30% for patients in IF support transplant using this conditioning regimen as a reasonable option. If TRM could be further improved, survival possibilities for these high-risk patients could become even more favorable. The use of targeted BU has decreased the hepatic and pulmonary toxicity previously associated with this drug, however mucositis remains a challenge with this regimen. Since this trial was initiated, advances in the use of palifermin 30 and targeted irradiation techniques such as radioimmunotherapy or total marrow irradiation, have the potential to decrease the incidence and severity of mucositis.
Based on the data from this phase-2 trial, City of Hope is currently accruing on a phase-1 trial of targeted IV BU, VP-16 and targeted total marrow irradiation using CT image-guided intensity modulated radiotherapy delivered by a Tomotherapy Hi-Art System (Tomotherapy Inc., Madison, WI, USA), 31 with tacrolimus/sirolimus GVHD prophylaxis in poor-risk AML patients. We anticipate further refinement of these favorable results in the future via the decreased extramedullary side effects of total marrow irradiation, a more effective GVHD regimen and the selection of AML patients most likely to benefit from this protocol. 
